Diligence memo · auto-generated · as of July 2, 2026
Thetis Pharmaceuticals LLC
Thetis Pharmaceuticals LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Thetis Pharmaceuticals LLC operates in Pharmaceuticals, based in Ridgefield.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Thetis Pharmaceuticals LLC has raised $15M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.7M on 2012-12-03.
Most recent recorded round closed around 2022-06-27.
Valuation (modeled)modeled
Provath models Thetis Pharmaceuticals LLC at approximately $14M (range $1.3M–$48M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.43× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 4.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 61% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.